BMY250117P52500
- 0.01
- 0.000.00%
Bristol-Myers Squibb Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $64 From $59
Reported Saturday, Bristol Myers Squibb Shares New Data Showing Opdivo Plus Yervoy Improves Outcomes Compared To Opdivo Alone in Colorectal Cancer
Bristol-Myers Squibb Hits 5-week High
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Is Bristol-Myers Squibb Company (BMY) the Best Stock to Invest In For Steady Dividends?
Bristol-Myers Squibb Company (NYSE:BMY) Is Largely Controlled by Institutional Shareholders Who Own 77% of the Company
Revenue is expected to increase by 932%! Baile Tianheng: Expected to turn a profit in 2024.
① Aside from the initial payment of 0.8 billion dollars, the cooperation announcement at that time indicated that the potential total Trade amount between BMS and Bai Li Tian Heng's subsidiary could reach up to 8.4 billion dollars. ② As of now, Bai Li Tian Heng has advanced three drugs to the Phase III registration clinical research stage, developed ten early-stage core clinical Assets, and a series of preclinical Innovative Drugs projects.
Hong Kong stocks movement | Ark Health surged 19.5% at one point after reaching a Global Strategy cooperation with Bristol-Myers Squibb in China.
Gelonghui January 20 | Ark Health (6086.HK) initially surged 19.5% to HKD 2.39. On the news front, on December 16, Ark Health signed a strategic cooperation agreement with Bristol-Myers Squibb in China. The two parties will conduct in-depth cooperation in areas such as the construction of digital health platforms and the upgrade of Internet health management models, and jointly explore new pathways for innovative development in Digital Health. It is reported that this strategic cooperation will focus on in-depth collaboration regarding the treatment drug riblocer and the psoriasis treatment drug secukinumab, exploring innovative digital marketing project management models. Notably, riblocer
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks
'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC
Bristol-Myers Squibb (NYSE:BMY) Places Faith In Cobenfy for Alzheimer's Treatment
Express News | U.S. Says Other Drugs on Medicare Drug Price List Include Pomalyst, Ibrance and Calquence
Positive Outlook for Bristol-Myers Squibb With Promising Market Access and Societal Benefits of Cobenfy
Bristol-Myers Squibb Company's (NYSE:BMY) Business And Shares Still Trailing The Industry
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
Bristol-Myers Squibb (BMY.US) CEO discusses the efficacy of the new schizophrenia medication, being Bullish on the company's prospects.
Bristol-Myers Squibb's CEO Chris Boerner introduced the company's new drug Cobenfy in an interview, which can be used to treat mental illnesses such as schizophrenia.
Bristol Myers Squibb CEO Describes New Drug for Treating Schizophrenia
Bristol Sees Annual $1.5B in Cost Savings by End of 2025